

EMA/251128/2023

European Medicines Agency decision P/0271/2023

of 14 July 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nizaracianine trifluate (EMEA-003367-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0271/2023

of 14 June 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for nizaracianine trifluate (EMA-003367-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 3 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Curadel Surgical Innovations, Inc. on 21 November 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 May 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for nizaracianine trifluate, powder for solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for nizaracianine trifluate, powder for solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for nizaracianine trifluate, powder for solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Curadel Surgical Innovations, Inc., 11 Erie Drive, 01760 – Natick, USA.

EMA/PDCO/158870/2023
Amsterdam, 26 May 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-003367-PIP01-22

Scope of the application

Active substance(s):

Nizaracianine trifluate

Invented name and authorisation status:

See Annex II

Condition(s):

Visualisation of ureter

Pharmaceutical form(s):

Powder for solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Curadel Surgical Innovations, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Curadel Surgical Innovations, Inc. submitted for agreement to the European Medicines Agency on 21 November 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 03 January 2023.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Visualisation of ureter

The waiver applies to:

- the paediatric population from birth to less than 1 month of age;
- powder for solution for injection, intravenous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Visualisation of ureter

2.1.1. Indication(s) targeted by the PIP

Visualisation of the ureters during surgery

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 month of age to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 Open-label, uncontrolled study to evaluate intraoperative ureter visualisation when using nizaracianine trifluate with near-infrared fluorescence (NIR-F) compared to white light (WL) in children from 1 month of age to less than 18 years of age undergoing abdominopelvic surgery.
Modelling and simulation studies	Study 2 Modelling and simulation study to derive dosing of nizaracianine trifluate for intraoperative ureter visualisation in children from 1

	<p>month to less than 18 years of age undergoing abdominopelvic surgery.</p> <p>Study 3</p> <p>Modelling and simulation study to document pharmacokinetic (PK) and pharmacodynamic (PD) data relationship of nizaracianine trifluate for intraoperative ureter visualisation in children from 1 month to less than 18 years of age undergoing abdominopelvic surgery.</p>
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.